89 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
.
Research & development strategy: Ovid is focused on the development of novel, targeted small molecules that have the potential to be first-in-class … that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid’s ability to identify
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
. If successfully commercialized, this may provide significant non-dilutive capital to further fund Ovid and its pipeline.
Scientific strategy: Ovid … that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid’s ability to identify
424B5
17gm782ajv
15 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
lhuw ghjum8xiozkkt8s
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
56p7dw2
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
EX-99.1
asmqko
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
EX-99.1
9jb5fzlpux4erz9qmfwf
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
EX-99.1
96uwvn
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
EX-99.1
3rl03wpnb vy7xz
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
EX-99.1
4y27r chyeq3lywgvn
1 May 23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
4:17pm
8-K
EX-99.1
f2v0rw fiklme52k2r3
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am